XENCOR INC (XNCR) Stock News

NASDAQ:XNCR - US98401F1057 - Common Stock

8.13 USD

+0.08 (+0.99%)

Last: 8/29/2025, 8:00:22 PM

8.13 USD

0 (0%)

After Hours: 8/29/2025, 8:00:22 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XNCR Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Xencor, Inc.

Xencor to Participate at Upcoming Investor Conferences

23 days ago - By: Zacks Investment Research - Mentions: PSTV

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

23 days ago - By: The Motley Fool

Xencor (XNCR) Q2 Revenue Jumps 82%

23 days ago - By: Xencor, Inc.

Xencor Reports Second Quarter 2025 Financial Results

a month ago - By: Xencor, Inc.

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

4 months ago - By: Benzinga - Mentions: WORX MTNB VYGR AQB ...

12 Health Care Stocks Moving In Friday's After-Market Session

4 months ago - By: Yahoo Finance - Mentions: GILD VZ AMZN WMT ...

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

4 months ago - By: Zacks Investment Research - Mentions: AKBA

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Xencor, Inc.

Xencor Reports First Quarter 2025 Financial Results

4 months ago - By: Zacks Investment Research - Mentions: CPRX

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

9 months ago - By: Benzinga

Critical Insights From Xencor Analyst Ratings: What You Need To Know

4 months ago - By: Xencor, Inc.

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

6 months ago - By: Xencor, Inc.

Xencor Appoints Todd Simpson to Board of Directors

6 months ago - By: Xencor, Inc.

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

a year ago - By: BusinessInsider

News Image

XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024

a year ago - By: InvestorPlace

XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024

9 months ago - By: Xencor, Inc.

Xencor to Participate at Upcoming Investor Conferences

10 months ago - By: Xencor, Inc.

Xencor Reports Third Quarter 2024 Financial Results

10 months ago - By: Xencor, Inc.

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

a year ago - By: Xencor, Inc.

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

a year ago - By: Xencor, Inc.

Xencor Announces Upcoming Change to Board of Directors

a year ago - By: Xencor, Inc.

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

a year ago - By: Xencor, Inc.

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

a year ago - By: Xencor, Inc.

Xencor Announces Proposed Public Offering of Common Stock

a year ago - By: Xencor, Inc.

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

a year ago - By: Xencor, Inc.

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

a year ago - By: Xencor, Inc.

Xencor Reports Second Quarter 2024 Financial Results